View ValuationSyncom Formulations (India) 将来の成長Future 基準チェック /06現在、 Syncom Formulations (India)の成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長16.6%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesValuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹12.25, the stock trades at a trailing P/E ratio of 16.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 88% over the past three years.Reported Earnings • Feb 14Third quarter 2026 earnings released: EPS: ₹0.23 (vs ₹0.14 in 3Q 2025)Third quarter 2026 results: EPS: ₹0.23 (up from ₹0.14 in 3Q 2025). Revenue: ₹1.21b (down 5.4% from 3Q 2025). Net income: ₹189.1m (up 45% from 3Q 2025). Profit margin: 16% (up from 10% in 3Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth.分析記事 • Feb 02Here's Why We Think Syncom Formulations (India) (NSE:SYNCOMF) Is Well Worth WatchingFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Reported Earnings • Nov 13Second quarter 2026 earnings released: EPS: ₹0.18 (vs ₹0.16 in 2Q 2025)Second quarter 2026 results: EPS: ₹0.18 (up from ₹0.16 in 2Q 2025). Revenue: ₹1.27b (up 24% from 2Q 2025). Net income: ₹166.0m (up 49% from 2Q 2025). Profit margin: 13% (up from 11% in 2Q 2025). The increase in margin was driven by higher revenue.お知らせ • Oct 01Syncom Formulations (India) Limited Approves Appointment of Shri Ankit Kedarmal as Executive ChairmanSyncom Formulations (India) Limited at its AGM held on September 29, 2025, approved appointment of Shri Ankit Kedarmal as Executive Chairman and to approve the remuneration payable to him.お知らせ • Sep 04+ 2 more updatesSyncom Formulations (India) Limited to Report Q3, 2026 Results on Feb 14, 2026Syncom Formulations (India) Limited announced that they will report Q3, 2026 results on Feb 14, 2026お知らせ • Aug 11Syncom Formulations (India) Limited, Annual General Meeting, Sep 29, 2025Syncom Formulations (India) Limited, Annual General Meeting, Sep 29, 2025, at 14:00 Indian Standard Time.Reported Earnings • Aug 09First quarter 2026 earnings released: EPS: ₹0.21 (vs ₹0.11 in 1Q 2025)First quarter 2026 results: EPS: ₹0.21 (up from ₹0.11 in 1Q 2025). Revenue: ₹1.23b (up 41% from 1Q 2025). Net income: ₹157.5m (up 106% from 1Q 2025). Profit margin: 13% (up from 8.7% in 1Q 2025). The increase in margin was driven by higher revenue.お知らせ • Aug 08+ 1 more updateSyncom Formulations (India) Limited Announces CFO ChangesSyncom Formulations (India) Limited announced that at its board meeting held on August 08, 2025, noted and accepted the resignation of Shri Ankit Kedarnal Bankda from the position of Chief Financial Officer (CFO), with effect from the close of business hours on August 08, 2025. The company approved the appointment of Shri Rahul Vijay Bankda as Chief Financial Officer (CFO) of the Company, with effect from August 09, 2025.お知らせ • Aug 02Syncom Formulations (India) Limited to Report Q1, 2026 Results on Aug 08, 2025Syncom Formulations (India) Limited announced that they will report Q1, 2026 results on Aug 08, 2025New Risk • May 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Reported Earnings • May 21Full year 2025 earnings released: EPS: ₹0.57 (vs ₹0.27 in FY 2024)Full year 2025 results: EPS: ₹0.57 (up from ₹0.27 in FY 2024). Revenue: ₹4.82b (up 83% from FY 2024). Net income: ₹494.3m (up 95% from FY 2024). Profit margin: 10% (in line with FY 2024).分析記事 • May 19Syncom Formulations (India) Limited's (NSE:SYNCOMF) Business Is Trailing The Market But Its Shares Aren'tWhen close to half the companies in India have price-to-earnings ratios (or "P/E's") below 27x, you may consider Syncom...Valuation Update With 7 Day Price Move • May 16Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹17.49, the stock trades at a trailing P/E ratio of 42x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 31% over the past year.お知らせ • May 13Syncom Formulations (India) Limited to Report Q4, 2025 Results on May 19, 2025Syncom Formulations (India) Limited announced that they will report Q4, 2025 results on May 19, 2025Valuation Update With 7 Day Price Move • Mar 24Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹18.24, the stock trades at a trailing P/E ratio of 43.8x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 53% over the past year.Valuation Update With 7 Day Price Move • Mar 10Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹17.11, the stock trades at a trailing P/E ratio of 41.1x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 29% over the past year.分析記事 • Mar 08Should You Be Adding Syncom Formulations (India) (NSE:SYNCOMF) To Your Watchlist Today?It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Reported Earnings • Feb 11Third quarter 2025 earnings released: EPS: ₹0.14 (vs ₹0.09 in 3Q 2024)Third quarter 2025 results: EPS: ₹0.14 (up from ₹0.09 in 3Q 2024). Revenue: ₹1.32b (up 102% from 3Q 2024). Net income: ₹130.0m (up 86% from 3Q 2024). Profit margin: 9.9% (in line with 3Q 2024).お知らせ • Feb 03Syncom Formulations (India) Limited to Report Q3, 2025 Results on Feb 12, 2025Syncom Formulations (India) Limited announced that they will report Q3, 2025 results on Feb 12, 2025分析記事 • Jan 11Does Syncom Formulations (India) (NSE:SYNCOMF) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Dec 10Getting In Cheap On Syncom Formulations (India) Limited (NSE:SYNCOMF) Is UnlikelyWith a price-to-earnings (or "P/E") ratio of 67x Syncom Formulations (India) Limited ( NSE:SYNCOMF ) may be sending...Reported Earnings • Nov 12Second quarter 2025 earnings released: EPS: ₹0.16 (vs ₹0.08 in 2Q 2024)Second quarter 2025 results: EPS: ₹0.16 (up from ₹0.08 in 2Q 2024). Revenue: ₹1.06b (up 67% from 2Q 2024). Net income: ₹111.1m (up 71% from 2Q 2024). Profit margin: 10% (in line with 2Q 2024).お知らせ • Nov 05Syncom Formulations (India) Limited to Report Q2, 2025 Results on Nov 11, 2024Syncom Formulations (India) Limited announced that they will report Q2, 2025 results on Nov 11, 2024Valuation Update With 7 Day Price Move • Sep 19Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹22.28, the stock trades at a trailing P/E ratio of 73.2x. Average trailing P/E is 42x in the Pharmaceuticals industry in India. Total returns to shareholders of 162% over the past year.New Risk • Sep 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.分析記事 • Aug 30Syncom Formulations (India) Limited's (NSE:SYNCOMF) 27% Price Boost Is Out Of Tune With EarningsSyncom Formulations (India) Limited ( NSE:SYNCOMF ) shares have continued their recent momentum with a 27% gain in the...Valuation Update With 7 Day Price Move • Aug 21Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹19.07, the stock trades at a trailing P/E ratio of 62.9x. Average trailing P/E is 37x in the Pharmaceuticals industry in India. Total returns to shareholders of 112% over the past year.お知らせ • Aug 13Syncom Formulations (India) Limited, Annual General Meeting, Sep 30, 2024Syncom Formulations (India) Limited, Annual General Meeting, Sep 30, 2024, at 14:00 Indian Standard Time.Reported Earnings • Aug 13First quarter 2025 earnings released: EPS: ₹0.11 (vs ₹0.07 in 1Q 2024)First quarter 2025 results: EPS: ₹0.11 (up from ₹0.07 in 1Q 2024). Revenue: ₹885.9m (up 48% from 1Q 2024). Net income: ₹76.3m (up 74% from 1Q 2024). Profit margin: 8.6% (up from 7.3% in 1Q 2024). The increase in margin was driven by higher revenue.お知らせ • Aug 02Syncom Formulations (India) Limited to Report Q1, 2025 Results on Aug 12, 2024Syncom Formulations (India) Limited announced that they will report Q1, 2025 results on Aug 12, 2024分析記事 • Jul 16Syncom Formulations (India) Limited's (NSE:SYNCOMF) 27% Price Boost Is Out Of Tune With EarningsSyncom Formulations (India) Limited ( NSE:SYNCOMF ) shareholders have had their patience rewarded with a 27% share...Valuation Update With 7 Day Price Move • Jul 15Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹16.01, the stock trades at a trailing P/E ratio of 59.5x. Average trailing P/E is 35x in the Pharmaceuticals industry in India. Total returns to shareholders of 112% over the past year.Reported Earnings • May 19Full year 2024 earnings released: EPS: ₹0.34 (vs ₹0.22 in FY 2023)Full year 2024 results: EPS: ₹0.34 (up from ₹0.22 in FY 2023). Revenue: ₹2.77b (up 24% from FY 2023). Net income: ₹253.1m (up 26% from FY 2023). Profit margin: 9.1% (up from 8.9% in FY 2023). The increase in margin was driven by higher revenue.Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹12.85, the stock trades at a trailing P/E ratio of 46x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 96% over the past year.お知らせ • Mar 29Syncom Formulations (India) Limited Announces Board ChangesSyncom Formulations (India) Limited announced that tenure completion of Shri Vinod Kumar Kabra, Shri Krishna Das Neema and Shri Praveen Jindal Independent Director(s) of the Company appointed w.e.f., 1 April, 2014 for a tenure of five (5) year and further were re-appointed w.e.f. 1 April, 2019 for further tenure of five (5) year in the category of Non-Executive Independent Directors of the company w.e.f. close of working hour of 31 March, 2024.分析記事 • Mar 21Some Syncom Formulations (India) Limited (NSE:SYNCOMF) Shareholders Look For Exit As Shares Take 28% PoundingSyncom Formulations (India) Limited ( NSE:SYNCOMF ) shares have had a horrible month, losing 28% after a relatively...Reported Earnings • Feb 15Third quarter 2024 earnings released: EPS: ₹0.09 (vs ₹0.06 in 3Q 2023)Third quarter 2024 results: EPS: ₹0.09 (up from ₹0.06 in 3Q 2023). Revenue: ₹696.9m (up 22% from 3Q 2023). Net income: ₹70.0m (up 69% from 3Q 2023). Profit margin: 10.0% (up from 7.2% in 3Q 2023). The increase in margin was driven by higher revenue.分析記事 • Dec 29Syncom Formulations (India) Limited's (NSE:SYNCOMF) 27% Price Boost Is Out Of Tune With EarningsDespite an already strong run, Syncom Formulations (India) Limited ( NSE:SYNCOMF ) shares have been powering on, with a...Valuation Update With 7 Day Price Move • Dec 26Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹14.15, the stock trades at a trailing P/E ratio of 56.5x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 55% over the past year.Valuation Update With 7 Day Price Move • Nov 23Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹12.65, the stock trades at a trailing P/E ratio of 50.6x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 62% over the past year.Reported Earnings • Nov 11Second quarter 2024 earnings released: EPS: ₹0.08 (vs ₹0.06 in 2Q 2023)Second quarter 2024 results: EPS: ₹0.08 (up from ₹0.06 in 2Q 2023). Revenue: ₹678.4m (up 25% from 2Q 2023). Net income: ₹65.1m (up 81% from 2Q 2023). Profit margin: 9.6% (up from 6.6% in 2Q 2023). The increase in margin was driven by higher revenue.Valuation Update With 7 Day Price Move • Nov 09Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹10.30, the stock trades at a trailing P/E ratio of 47x. Average trailing P/E is 31x in the Pharmaceuticals industry in India.お知らせ • Sep 05+ 2 more updatesSyncom Formulations (India) Limited to Report Q3, 2024 Results on Feb 14, 2024Syncom Formulations (India) Limited announced that they will report Q3, 2024 results on Feb 14, 2024お知らせ • Aug 15Syncom Formulations (India) Limited, Annual General Meeting, Sep 26, 2023Syncom Formulations (India) Limited, Annual General Meeting, Sep 26, 2023, at 15:00 Indian Standard Time.Reported Earnings • Aug 15First quarter 2024 earnings releasedFirst quarter 2024 results: EPS: ₹0.07. Revenue: ₹617.1m (up 20% from 1Q 2023). Net income: ₹44.0m (up 14% from 1Q 2023). Profit margin: 7.1% (down from 7.5% in 1Q 2023). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Aug 07Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹9.25, the stock trades at a trailing P/E ratio of 43.4x. Average trailing P/E is 30x in the Pharmaceuticals industry in India.お知らせ • Aug 04Syncom Formulations (India) Limited to Report Q1, 2024 Results on Aug 14, 2023Syncom Formulations (India) Limited announced that they will report Q1, 2024 results on Aug 14, 2023Reported Earnings • Jun 02Full year 2023 earnings released: EPS: ₹0.24 (vs ₹0.24 in FY 2022)Full year 2023 results: EPS: ₹0.24. Revenue: ₹2.39b (up 8.7% from FY 2022). Net income: ₹200.7m (up 1.4% from FY 2022). Profit margin: 8.4% (down from 9.0% in FY 2022). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Mar 28Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹5.00, the stock trades at a trailing P/E ratio of 28.7x. Average trailing P/E is 23x in the Pharmaceuticals industry in India.Reported Earnings • Feb 14Third quarter 2023 earnings released: EPS: ₹0.06 (vs ₹0.07 in 3Q 2022)Third quarter 2023 results: EPS: ₹0.06. Revenue: ₹593.6m (up 3.7% from 3Q 2022). Net income: ₹41.4m (up 3.3% from 3Q 2022). Profit margin: 7.0% (in line with 3Q 2022).お知らせ • Feb 02Syncom Formulations (India) Limited to Report Q3, 2023 Results on Feb 13, 2023Syncom Formulations (India) Limited announced that they will report Q3, 2023 results on Feb 13, 2023分析記事 • Dec 27Syncom Formulations (India) Limited's (NSE:SYNCOMF) Shares Climb 26% But Its Business Is Yet to Catch UpSyncom Formulations (India) Limited ( NSE:SYNCOMF ) shareholders would be excited to see that the share price has had a...Valuation Update With 7 Day Price Move • Dec 23Investor sentiment improved over the past weekAfter last week's 24% share price gain to ₹9.70, the stock trades at a trailing P/E ratio of 56.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in India.Board Change • Nov 21Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. No experienced directors. 6 highly experienced directors. Additional Non-Executive Independent Woman Director Ruchi Jindal was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Syncom Formulations (India) は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測NSEI:SYNCOMF - アナリストの将来予測と過去の財務データ ( )INR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20255,026690N/AN/AN/A9/30/20255,150631555736N/A6/30/20254,947576N/AN/AN/A3/31/20254,650494135234N/A12/31/20243,907391N/AN/AN/A9/30/20243,283331-90-51N/A6/30/20242,908286N/AN/AN/A3/31/20242,634253-141-60N/A12/31/20232,498264N/AN/AN/A9/30/20232,42023535170N/A6/30/20232,327206N/AN/AN/A3/31/20232,243201-101105N/A12/31/20222,215164N/AN/AN/A9/30/20222,213162-17650N/A6/30/20222,198183N/AN/AN/A3/31/20222,19719850163N/A12/31/20212,270220N/AN/AN/A9/30/20212,539280-83-70N/A6/30/20212,668316N/AN/AN/A3/31/20212,448292-47-21N/A12/31/20202,223257N/AN/AN/A9/30/20201,90519294113N/A6/30/20201,809143N/AN/AN/A3/31/20202,0551434159N/A12/31/20192,237130N/AN/AN/A9/30/20192,191133N/A87N/A6/30/20192,077120N/AN/AN/A3/31/20191,868111N/A43N/A12/31/20181,648106N/AN/AN/A9/30/20181,56697N/AN/AN/A6/30/20181,50587N/AN/AN/A3/31/20181,58686N/A-16N/A3/31/20171,848105N/A138N/A3/31/20161,839104N/A241N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SYNCOMFの予測収益成長が 貯蓄率 ( 6.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: SYNCOMFの収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: SYNCOMFの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: SYNCOMFの収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: SYNCOMFの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SYNCOMFの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 19:00終値2026/05/22 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Syncom Formulations (India) Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹12.25, the stock trades at a trailing P/E ratio of 16.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 88% over the past three years.
Reported Earnings • Feb 14Third quarter 2026 earnings released: EPS: ₹0.23 (vs ₹0.14 in 3Q 2025)Third quarter 2026 results: EPS: ₹0.23 (up from ₹0.14 in 3Q 2025). Revenue: ₹1.21b (down 5.4% from 3Q 2025). Net income: ₹189.1m (up 45% from 3Q 2025). Profit margin: 16% (up from 10% in 3Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth.
分析記事 • Feb 02Here's Why We Think Syncom Formulations (India) (NSE:SYNCOMF) Is Well Worth WatchingFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Reported Earnings • Nov 13Second quarter 2026 earnings released: EPS: ₹0.18 (vs ₹0.16 in 2Q 2025)Second quarter 2026 results: EPS: ₹0.18 (up from ₹0.16 in 2Q 2025). Revenue: ₹1.27b (up 24% from 2Q 2025). Net income: ₹166.0m (up 49% from 2Q 2025). Profit margin: 13% (up from 11% in 2Q 2025). The increase in margin was driven by higher revenue.
お知らせ • Oct 01Syncom Formulations (India) Limited Approves Appointment of Shri Ankit Kedarmal as Executive ChairmanSyncom Formulations (India) Limited at its AGM held on September 29, 2025, approved appointment of Shri Ankit Kedarmal as Executive Chairman and to approve the remuneration payable to him.
お知らせ • Sep 04+ 2 more updatesSyncom Formulations (India) Limited to Report Q3, 2026 Results on Feb 14, 2026Syncom Formulations (India) Limited announced that they will report Q3, 2026 results on Feb 14, 2026
お知らせ • Aug 11Syncom Formulations (India) Limited, Annual General Meeting, Sep 29, 2025Syncom Formulations (India) Limited, Annual General Meeting, Sep 29, 2025, at 14:00 Indian Standard Time.
Reported Earnings • Aug 09First quarter 2026 earnings released: EPS: ₹0.21 (vs ₹0.11 in 1Q 2025)First quarter 2026 results: EPS: ₹0.21 (up from ₹0.11 in 1Q 2025). Revenue: ₹1.23b (up 41% from 1Q 2025). Net income: ₹157.5m (up 106% from 1Q 2025). Profit margin: 13% (up from 8.7% in 1Q 2025). The increase in margin was driven by higher revenue.
お知らせ • Aug 08+ 1 more updateSyncom Formulations (India) Limited Announces CFO ChangesSyncom Formulations (India) Limited announced that at its board meeting held on August 08, 2025, noted and accepted the resignation of Shri Ankit Kedarnal Bankda from the position of Chief Financial Officer (CFO), with effect from the close of business hours on August 08, 2025. The company approved the appointment of Shri Rahul Vijay Bankda as Chief Financial Officer (CFO) of the Company, with effect from August 09, 2025.
お知らせ • Aug 02Syncom Formulations (India) Limited to Report Q1, 2026 Results on Aug 08, 2025Syncom Formulations (India) Limited announced that they will report Q1, 2026 results on Aug 08, 2025
New Risk • May 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Reported Earnings • May 21Full year 2025 earnings released: EPS: ₹0.57 (vs ₹0.27 in FY 2024)Full year 2025 results: EPS: ₹0.57 (up from ₹0.27 in FY 2024). Revenue: ₹4.82b (up 83% from FY 2024). Net income: ₹494.3m (up 95% from FY 2024). Profit margin: 10% (in line with FY 2024).
分析記事 • May 19Syncom Formulations (India) Limited's (NSE:SYNCOMF) Business Is Trailing The Market But Its Shares Aren'tWhen close to half the companies in India have price-to-earnings ratios (or "P/E's") below 27x, you may consider Syncom...
Valuation Update With 7 Day Price Move • May 16Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹17.49, the stock trades at a trailing P/E ratio of 42x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 31% over the past year.
お知らせ • May 13Syncom Formulations (India) Limited to Report Q4, 2025 Results on May 19, 2025Syncom Formulations (India) Limited announced that they will report Q4, 2025 results on May 19, 2025
Valuation Update With 7 Day Price Move • Mar 24Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹18.24, the stock trades at a trailing P/E ratio of 43.8x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 53% over the past year.
Valuation Update With 7 Day Price Move • Mar 10Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹17.11, the stock trades at a trailing P/E ratio of 41.1x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 29% over the past year.
分析記事 • Mar 08Should You Be Adding Syncom Formulations (India) (NSE:SYNCOMF) To Your Watchlist Today?It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Reported Earnings • Feb 11Third quarter 2025 earnings released: EPS: ₹0.14 (vs ₹0.09 in 3Q 2024)Third quarter 2025 results: EPS: ₹0.14 (up from ₹0.09 in 3Q 2024). Revenue: ₹1.32b (up 102% from 3Q 2024). Net income: ₹130.0m (up 86% from 3Q 2024). Profit margin: 9.9% (in line with 3Q 2024).
お知らせ • Feb 03Syncom Formulations (India) Limited to Report Q3, 2025 Results on Feb 12, 2025Syncom Formulations (India) Limited announced that they will report Q3, 2025 results on Feb 12, 2025
分析記事 • Jan 11Does Syncom Formulations (India) (NSE:SYNCOMF) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Dec 10Getting In Cheap On Syncom Formulations (India) Limited (NSE:SYNCOMF) Is UnlikelyWith a price-to-earnings (or "P/E") ratio of 67x Syncom Formulations (India) Limited ( NSE:SYNCOMF ) may be sending...
Reported Earnings • Nov 12Second quarter 2025 earnings released: EPS: ₹0.16 (vs ₹0.08 in 2Q 2024)Second quarter 2025 results: EPS: ₹0.16 (up from ₹0.08 in 2Q 2024). Revenue: ₹1.06b (up 67% from 2Q 2024). Net income: ₹111.1m (up 71% from 2Q 2024). Profit margin: 10% (in line with 2Q 2024).
お知らせ • Nov 05Syncom Formulations (India) Limited to Report Q2, 2025 Results on Nov 11, 2024Syncom Formulations (India) Limited announced that they will report Q2, 2025 results on Nov 11, 2024
Valuation Update With 7 Day Price Move • Sep 19Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹22.28, the stock trades at a trailing P/E ratio of 73.2x. Average trailing P/E is 42x in the Pharmaceuticals industry in India. Total returns to shareholders of 162% over the past year.
New Risk • Sep 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
分析記事 • Aug 30Syncom Formulations (India) Limited's (NSE:SYNCOMF) 27% Price Boost Is Out Of Tune With EarningsSyncom Formulations (India) Limited ( NSE:SYNCOMF ) shares have continued their recent momentum with a 27% gain in the...
Valuation Update With 7 Day Price Move • Aug 21Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹19.07, the stock trades at a trailing P/E ratio of 62.9x. Average trailing P/E is 37x in the Pharmaceuticals industry in India. Total returns to shareholders of 112% over the past year.
お知らせ • Aug 13Syncom Formulations (India) Limited, Annual General Meeting, Sep 30, 2024Syncom Formulations (India) Limited, Annual General Meeting, Sep 30, 2024, at 14:00 Indian Standard Time.
Reported Earnings • Aug 13First quarter 2025 earnings released: EPS: ₹0.11 (vs ₹0.07 in 1Q 2024)First quarter 2025 results: EPS: ₹0.11 (up from ₹0.07 in 1Q 2024). Revenue: ₹885.9m (up 48% from 1Q 2024). Net income: ₹76.3m (up 74% from 1Q 2024). Profit margin: 8.6% (up from 7.3% in 1Q 2024). The increase in margin was driven by higher revenue.
お知らせ • Aug 02Syncom Formulations (India) Limited to Report Q1, 2025 Results on Aug 12, 2024Syncom Formulations (India) Limited announced that they will report Q1, 2025 results on Aug 12, 2024
分析記事 • Jul 16Syncom Formulations (India) Limited's (NSE:SYNCOMF) 27% Price Boost Is Out Of Tune With EarningsSyncom Formulations (India) Limited ( NSE:SYNCOMF ) shareholders have had their patience rewarded with a 27% share...
Valuation Update With 7 Day Price Move • Jul 15Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹16.01, the stock trades at a trailing P/E ratio of 59.5x. Average trailing P/E is 35x in the Pharmaceuticals industry in India. Total returns to shareholders of 112% over the past year.
Reported Earnings • May 19Full year 2024 earnings released: EPS: ₹0.34 (vs ₹0.22 in FY 2023)Full year 2024 results: EPS: ₹0.34 (up from ₹0.22 in FY 2023). Revenue: ₹2.77b (up 24% from FY 2023). Net income: ₹253.1m (up 26% from FY 2023). Profit margin: 9.1% (up from 8.9% in FY 2023). The increase in margin was driven by higher revenue.
Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹12.85, the stock trades at a trailing P/E ratio of 46x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 96% over the past year.
お知らせ • Mar 29Syncom Formulations (India) Limited Announces Board ChangesSyncom Formulations (India) Limited announced that tenure completion of Shri Vinod Kumar Kabra, Shri Krishna Das Neema and Shri Praveen Jindal Independent Director(s) of the Company appointed w.e.f., 1 April, 2014 for a tenure of five (5) year and further were re-appointed w.e.f. 1 April, 2019 for further tenure of five (5) year in the category of Non-Executive Independent Directors of the company w.e.f. close of working hour of 31 March, 2024.
分析記事 • Mar 21Some Syncom Formulations (India) Limited (NSE:SYNCOMF) Shareholders Look For Exit As Shares Take 28% PoundingSyncom Formulations (India) Limited ( NSE:SYNCOMF ) shares have had a horrible month, losing 28% after a relatively...
Reported Earnings • Feb 15Third quarter 2024 earnings released: EPS: ₹0.09 (vs ₹0.06 in 3Q 2023)Third quarter 2024 results: EPS: ₹0.09 (up from ₹0.06 in 3Q 2023). Revenue: ₹696.9m (up 22% from 3Q 2023). Net income: ₹70.0m (up 69% from 3Q 2023). Profit margin: 10.0% (up from 7.2% in 3Q 2023). The increase in margin was driven by higher revenue.
分析記事 • Dec 29Syncom Formulations (India) Limited's (NSE:SYNCOMF) 27% Price Boost Is Out Of Tune With EarningsDespite an already strong run, Syncom Formulations (India) Limited ( NSE:SYNCOMF ) shares have been powering on, with a...
Valuation Update With 7 Day Price Move • Dec 26Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹14.15, the stock trades at a trailing P/E ratio of 56.5x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 55% over the past year.
Valuation Update With 7 Day Price Move • Nov 23Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹12.65, the stock trades at a trailing P/E ratio of 50.6x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 62% over the past year.
Reported Earnings • Nov 11Second quarter 2024 earnings released: EPS: ₹0.08 (vs ₹0.06 in 2Q 2023)Second quarter 2024 results: EPS: ₹0.08 (up from ₹0.06 in 2Q 2023). Revenue: ₹678.4m (up 25% from 2Q 2023). Net income: ₹65.1m (up 81% from 2Q 2023). Profit margin: 9.6% (up from 6.6% in 2Q 2023). The increase in margin was driven by higher revenue.
Valuation Update With 7 Day Price Move • Nov 09Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹10.30, the stock trades at a trailing P/E ratio of 47x. Average trailing P/E is 31x in the Pharmaceuticals industry in India.
お知らせ • Sep 05+ 2 more updatesSyncom Formulations (India) Limited to Report Q3, 2024 Results on Feb 14, 2024Syncom Formulations (India) Limited announced that they will report Q3, 2024 results on Feb 14, 2024
お知らせ • Aug 15Syncom Formulations (India) Limited, Annual General Meeting, Sep 26, 2023Syncom Formulations (India) Limited, Annual General Meeting, Sep 26, 2023, at 15:00 Indian Standard Time.
Reported Earnings • Aug 15First quarter 2024 earnings releasedFirst quarter 2024 results: EPS: ₹0.07. Revenue: ₹617.1m (up 20% from 1Q 2023). Net income: ₹44.0m (up 14% from 1Q 2023). Profit margin: 7.1% (down from 7.5% in 1Q 2023). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Aug 07Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹9.25, the stock trades at a trailing P/E ratio of 43.4x. Average trailing P/E is 30x in the Pharmaceuticals industry in India.
お知らせ • Aug 04Syncom Formulations (India) Limited to Report Q1, 2024 Results on Aug 14, 2023Syncom Formulations (India) Limited announced that they will report Q1, 2024 results on Aug 14, 2023
Reported Earnings • Jun 02Full year 2023 earnings released: EPS: ₹0.24 (vs ₹0.24 in FY 2022)Full year 2023 results: EPS: ₹0.24. Revenue: ₹2.39b (up 8.7% from FY 2022). Net income: ₹200.7m (up 1.4% from FY 2022). Profit margin: 8.4% (down from 9.0% in FY 2022). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Mar 28Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹5.00, the stock trades at a trailing P/E ratio of 28.7x. Average trailing P/E is 23x in the Pharmaceuticals industry in India.
Reported Earnings • Feb 14Third quarter 2023 earnings released: EPS: ₹0.06 (vs ₹0.07 in 3Q 2022)Third quarter 2023 results: EPS: ₹0.06. Revenue: ₹593.6m (up 3.7% from 3Q 2022). Net income: ₹41.4m (up 3.3% from 3Q 2022). Profit margin: 7.0% (in line with 3Q 2022).
お知らせ • Feb 02Syncom Formulations (India) Limited to Report Q3, 2023 Results on Feb 13, 2023Syncom Formulations (India) Limited announced that they will report Q3, 2023 results on Feb 13, 2023
分析記事 • Dec 27Syncom Formulations (India) Limited's (NSE:SYNCOMF) Shares Climb 26% But Its Business Is Yet to Catch UpSyncom Formulations (India) Limited ( NSE:SYNCOMF ) shareholders would be excited to see that the share price has had a...
Valuation Update With 7 Day Price Move • Dec 23Investor sentiment improved over the past weekAfter last week's 24% share price gain to ₹9.70, the stock trades at a trailing P/E ratio of 56.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in India.
Board Change • Nov 21Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. No experienced directors. 6 highly experienced directors. Additional Non-Executive Independent Woman Director Ruchi Jindal was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.